 |
Indication & Dosage |
| |
| |
| Oral |
| TREATMENT OF DEPRESSION |
| Adult:
Initially, 50 mg once daily, may increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. |
| |
| Oral |
| MANAGEMENT OF OBSESSIVE-COMPULSIVE DISORDERS |
| Adult:
Initially, 50 mg daily. |
| |
| Oral |
| MANAGEMENT OF OBSESSIVE-COMPULSIVE DISORDERS |
| Child:
6-12 yr: Initially, 25 mg once daily; >12 yr: 50 mg once daily |
| |
| Oral |
| TREATMENT OF PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA |
| Adult:
Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. |
| |
| Oral |
| POSTTRAUMATIC STRESS DISORDER |
| Adult:
Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. |
| |
| Oral |
| TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER |
| Adult:
Initially, 50 mg daily. May be given throughout the menstrual cycle or only during the luteal phase. May increase by 50 mg each cycle up to 150 mg daily for continuous dosing or 100 mg daily for luteal phase-only dosing. Patients who require 100 mg daily for luteal phase-only dosing should always start with 50 mg daily for the 1st 3 days of each luteal phase dosing period. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
History of hypomania and seizure disorders, hepatic and renal impairment, cardiac disease, recent MI, history of bleeding disorders, DM and angle-closure glaucoma. Discontinue treatment if seizures develop or if there is an increase in seizure frequency. Withdrawal should be gradual. Monitor for signs of clinical worsening, suicidality and unusual changes in behaviour especially during the initial treatment period or when there are dosage adjustments. Pregnancy and lactation. |
| |
|
| Adverse Drug Reactions |
Nausea, anorexia, dyspepsia, constipation, diarrhoea, dry mouth, flatulence, vomiting, ejaculation failure, increased sweating, somnolence, agitation, insomnia, headache, dizziness, fatigue, anxiety, nervousness, tremor, paraesthesia, decreased libido, rash, hot flushes, blurred vision. |
| |
|
| Interactions |
Concomitant admin with MAOIs can result in serious serotonin syndrome. May increase risk of delirium when used with antimuscarinics. Increased risk of extrapyramidal symptoms and neuroleptic malignant syndrome when used with aripiprazole. Serum levels may be reduced by carbamazepine. Concurrent use with dihydroergotamine or linezolid may lead to serotonin syndrome. May increase serum levels of lamotrigine and risk of toxicity. May increase serum levels of olanzapine, pimozide, risperidone, methadone, clozapine and amiodarone. Plasma levels may be increased by cimetidine and ritonavir. May increase the anticoagulant activity of warfarin and acenocoumarol. Co-admin with food increases peak plasma conc of sertraline. Plasma levels are increased by grapefruit juice. |
| |
|
|
|
